The degradatory enzyme FAAH has also been targeted for treating depression and epilepsy individually, with the general hypothesis that inhibiting or decreasing FAAH would increase levels of AEA, thereby alleviating symptoms. This evidence concerns the gene FAAH and depressive symptom measurement.